|
|
|
|
LEADER |
01456nam a2200349 u 4500 |
001 |
EB001999859 |
003 |
EBX01000000000000001162760 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
100 |
1 |
|
|a Weir, Arielle
|
245 |
0 |
0 |
|a Epinephrine auto-Injectors for anaphylaxis
|h Elektronische Ressource
|b a review of the clinical effectiveness, cost-effectiveness, and guidelines
|c Arielle Weir, Charlene Argáez
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, April 24, 2020
|
300 |
|
|
|a 1 PDF file (20 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Comparative Effectiveness Research
|
653 |
|
|
|a Injections, Intramuscular
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Anaphylaxis / drug therapy
|
653 |
|
|
|a Epinephrine / administration & dosage
|
653 |
|
|
|a Epinephrine / therapeutic use
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Self Administration
|
653 |
|
|
|a Practice Guidelines as Topic
|
700 |
1 |
|
|a Argáez, Charlene
|e [author]
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK563019
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|